高级检索
当前位置: 首页 > 详情页

Interferon regulatory factor-1 activates autophagy to aggravate hepatic ischemia-reperfusion injury via the P38/P62 pathway in mice

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]First Central Clinical College, Tianjin Medical University, Tianjin 300192, China. [2]Key Laboratory of Organ Transplantation of Tianjin, Tianjin 300071, China. [3]Oriental Organ Transplant Center, Tianjin First Central Hospital, Tianjin 300192, China. [4]Tianjin Nankai Hospital, Tianjin 300100, China. [5]Affiliated Hospital of Logistics University of Chinese People’s Armed Police Forces, Tianjin 300162, China. [6]Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. [7]Department of Immunology and Inflammation, Tianjin Medical University, Tianjin 300070, China
出处:
ISSN:

摘要:
Increasing evidence has linked autophagy to a detrimental role in hepatic ischemia-reperfusion (IR) injury (IRI). Here we focus on the role of interferon regulatory factor-1 (IRF-1) in regulating autophagy to aggravate hepatic IRI. We found that IRF-1 was up-regulated during hepatic IRI and was associated with an activation of the autophagic signaling. This increased IRF-1 expression, which was allied with high autophagic activity, amplified liver damage to IR, an effect which was abrogated by IRF-1 depletion. Moreover, IRF-1 contributed to P38 induced autophagic and apoptotic cell death, that can play a key role in liver dysfunction. The levels of P62 mRNA and protein were increased when P38 was activated and decreased when P38 was inhibited by SB203580. We conclude that IRF-1 functioned as a trigger to activate autophagy via P38 activation and that P62 was required for this P38-mediated autophagy. IRF-1 appears to exert a pivotal role in hepatic IRI, by predisposing hepatocytes to activate an autophagic pathway. Such an effect promotes autophagic cell death through the P38/P62 pathway. The identification of this novel pathway, that links expression levels of IRF-1 with autophagy, may provide new insights for the generation of novel protective therapies directed against hepatic IRI.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
最新[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区:
出版当年[2015]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2015版] 出版当年五年平均[2011-2015] 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者单位: [1]First Central Clinical College, Tianjin Medical University, Tianjin 300192, China. [2]Key Laboratory of Organ Transplantation of Tianjin, Tianjin 300071, China.
共同第一作者:
通讯作者:
通讯机构: [2]Key Laboratory of Organ Transplantation of Tianjin, Tianjin 300071, China. [3]Oriental Organ Transplant Center, Tianjin First Central Hospital, Tianjin 300192, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)